Neoplasms, Adipose Tissue: Clinical Trials

112 trials for Neoplasms, Adipose Tissue, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

53 completed, 18 recruiting, 13 unknown, 11 active not recruiting. 112 Phase 2, 22 Phase 1, 3 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 2112Completed 53, Recruiting 18, Unknown 13, Active not recruiting 11, Terminated 8, Withdrawn 6, Not yet recruiting 3
Phase 122Recruiting 9, Completed 6, Unknown 4, Terminated 2, Active not recruiting 1
Phase 33Completed 3

Follow Neoplasms, Adipose Tissue: new trials by email Literature Review of Neoplasms, Adipose Tissue trials Research Report on Neoplasms, Adipose Tissue

Trials (filtered) newest first · largest first

All 112 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Doxorubicin With or Without DT-7012 in Advanced Soft Tissue Sarcoma
DT-7012, Doxorubicin - Undifferentiated Pleomorphic Sarcoma (UPS), Dedifferentiated Liposarcoma (DDLPS)
Phase 2Not yet recruitingGustave Roussy, Cancer Campus, Grand Paris802027-02-012026-09-15
Testing the Anti-Cancer Drug, Brenetafusp (IMCF106C), in Rare Cancers
Anti-PRAME T-cell Receptor/Anti-CD3 scFv Fusion Protein IMC-F106C, Biopsy Procedure, Biospecimen Collection - Metastatic Myxoid Liposarcoma, Metastatic Synovial Sarcoma
Phase 2Not yet recruitingNational Cancer Institute (NCI)422027-01-192026-11-19
A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Soft Tissue Sarcoma
Lifileucel - Sarcoma, Soft Tissue Sarcoma (STS)
Phase 2RecruitingIovance Biotherapeutics, Inc.802026-10-022026-10-09
Testing the Addition of an Anti-cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (Gemcitabine) for Soft Tissue Sarcoma
Abemaciclib, Biopsy Procedure, Biospecimen Collection - Advanced Dedifferentiated Liposarcoma, Advanced Leiomyosarcoma
Phase 1 / Phase 2RecruitingNational Cancer Institute (NCI)742026-03-182026-10-21
Dose-escalated, Hypofractionated, Definitive Proton Radiotherapy for Patients With Inoperable Soft Tissue Sarcoma.
Definitive radiotherapy - Soft Tissue Sarcoma (STS), Soft Tissue Sarcoma Adult
Phase 2RecruitingOslo University Hospital402026-01-262026-01-28
Hypofractionated, 3-week, Preoperative Proton or X-ray Radiotherapy for Patients With Localized Soft Tissue Sarcoma
preoperative, Quality of life, Functional outcome - Soft Tissue Sarcoma (Excluding GIST), Soft Tissue Sarcoma Adult
Phase 2RecruitingOslo University Hospital1102026-01-262026-01-28
A Study of Pembrolizumab in People With Ultra-Rare Sarcomas
Pembrolizumab - Sarcoma
Phase 2RecruitingMemorial Sloan Kettering Cancer Center322025-12-042026-07-28
Safety and Preliminary Efficacy of SA53-OS in Patients With Locally Advanced or Metastatic Solid Tumors
SA53-OS (phase 1), SA53-OS (phase 2) - Solid Tumor
Phase 1 / Phase 2RecruitingLamassu Bio Inc552025-06-162026-11-09
Lipomas Treated With Subcutaneous Injections of Cooled or Warmed Sodium Chloride
Cooled Sodium Chloride Injection, Warmed Sodium Chloride Injection - Lipoma
Phase 1 / Phase 2RecruitingWest Virginia University202025-05-082026-04-29
STC-15 as a Part of Combination Therapy With Toripalimab in Selected Advanced Cancers and as Monotherapy in Participants With Selected Sarcomas
STC-15 in combination with toripalimab, STC-15 monotherapy - Solid Tumor, Sarcoma
Phase 1 / Phase 2RecruitingSTORM Therapeutics LTD1072025-05-052026-10-22
IO Combined With AI as First-line Treatment for Patients With Soft Tissue Sarcoma(TAIS)
Tislelizumab+liposomal doxorubicin+ifosfamide - Soft Tissue Sarcomas, Angiosarcoma
Phase 2RecruitingFudan University452025-02-252026-01-08
A Study of Mirdametinib in Combination With Palbociclib in People With Liposarcoma
Mirdametinib, Palbociclib - Well Differentiated Liposarcoma, Dedifferentiated Liposarcoma
Phase 1 / Phase 2RecruitingMemorial Sloan Kettering Cancer Center542025-02-192026-09-16
Study Evaluating Pembrolizumab +/- Olaparib in TLS Positive Selected Resectable STS Followed by Adjuvant Pembrolizumab
Pembrolizumab, Pembrolizumab and Olaparib, Pembrolizumab adjuvant - Cancer
Phase 2WithdrawnGustave Roussy, Cancer Campus, Grand Paris2025-01-012025-12-01
First-line Treatment of Advanced/unresectable DDLPS
Liposomal Doxorubicin (Doxil), Apatinib, Camrelizumab - Dedifferentiated Liposarcoma, Soft Tissue Sarcoma (STS)
Phase 2Not yet recruitingFudan University492024-12-012024-11-19
Ivonescimab in the Treatment of Multiple Advanced Tumors
Ivocizumab - Pheochromocytoma/Paraganglioma, Rhabdomyosarcoma
Phase 2RecruitingFudan University4002024-11-202025-08-24
Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors
Silmitasertib, Irinotecan, Temozolomide - Neuroblastoma, Ewing Sarcoma
Phase 1 / Phase 2RecruitingMilton S. Hershey Medical Center1042024-10-302026-11-12
A Phase 2, Open Label Study of PEmigatinib and REtifanlimab in Advanced Dedifferentiated LIposarcoma (PERELI)
Pemigatinib, Retifanlimab - Dedifferentiated Liposarcoma
Phase 2RecruitingLund University Hospital332024-06-202026-08-27
NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)
Surgical resection, Proton beam radiation therapy, Pazopanib - Adipocytic Neoplasm, Liposarcoma
Phase 1 / Phase 2RecruitingSt. Jude Children's Research Hospital1392024-03-272026-08-03
MASCT-I Combined With Doxorubicin and Ifosfamide for First-line Treatment of Advanced Soft Tissue Sarcoma
MASCT-I, Doxorubicin, Ifosfamide - Leiomyosarcoma, Liposarcoma
Phase 2RecruitingHRYZ Biotech Co.1482024-02-212025-07-24
Open-Label Study of the CDK4/6 Inhibitor SPH4336 in Subjects With Locally Advanced or Metastatic Liposarcomas
SPH4336 - Liposarcoma, Dedifferentiated
Phase 2TerminatedShanghai Pharma Biotherapeutics USA Inc.142023-08-312025-06-13

Showing 20 of 112. Sign in to see all of them.

Narrower conditions

Liposarcoma (91)  ·  Sarcoma (66)  ·  Leiomyosarcoma (48)  ·  Histiocytoma, Malignant Fibrous (33)  ·  Sarcoma, Synovial (33)  ·  Fibrosarcoma (27)  ·  Hemangiosarcoma (26)  ·  Neurofibrosarcoma (24)  ·  Rhabdomyosarcoma (22)  ·  Liposarcoma, Myxoid (21)  ·  Dermatofibrosarcoma (14)  ·  Osteosarcoma (13)  ·  Sarcoma, Alveolar Soft Part (13)  ·  Hemangiopericytoma, Malignant (11)  ·  Malignant mesenchymal tumor (10)

Broader conditions

Neoplasms by Histologic Type (112)  ·  Neoplasms, Connective and Soft Tissue (111)  ·  Neoplasms (106)  ·  Neoplasms, Connective Tissue (55)  ·  Neoplasms, Muscle Tissue (52)  ·  Neoplasms, Fibrous Tissue (42)  ·  Sarcoma (38)  ·  Histiocytoma (33)  ·  Neoplasms, Nerve Tissue (31)  ·  Nervous System Diseases (27)  ·  Neoplasms, Vascular Tissue (26)  ·  Nervous System Neoplasms (24)  ·  Neurofibroma (24)  ·  Neuromuscular Diseases (24)

Interventions

Doxorubicin (11)  ·  Trabectedin (8)  ·  Radiotherapy (6)  ·  pazopanib (6)  ·  Biopsy (5)  ·  Cyclophosphamide (5)  ·  Docetaxel (4)  ·  Gemcitabine (4)  ·  Ifosfamide (4)  ·  palbociclib (4)  ·  pembrolizumab (4)  ·  Imatinib Mesylate (3)  ·  Magnetic Resonance Spectroscopy (3)  ·  Radiation (3)  ·  Radiation Dose Hypofractionation (3)

Sponsors

National Cancer Institute (NCI) (13)  ·  European Organisation for Research and Treatment of Cancer - EORTC (7)  ·  Memorial Sloan Kettering Cancer Center (7)  ·  Dana-Farber Cancer Institute (4)  ·  Fudan University (3)  ·  Maria Sklodowska-Curie National Research Institute of Oncology (3)  ·  Alliance for Clinical Trials in Oncology (2)  ·  Brown University (2)  ·  Fred Hutchinson Cancer Center (2)  ·  Grupo Espanol de Investigacion en Sarcomas (2)  ·  Gustave Roussy, Cancer Campus, Grand Paris (2)  ·  Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (2)  ·  M.D. Anderson Cancer Center (2)  ·  Novartis Pharmaceuticals (2)  ·  Oslo University Hospital (2)

Countries

United States (73)  ·  France (14)  ·  Canada (11)  ·  United Kingdom (11)  ·  Spain (10)  ·  Belgium (8)  ·  China (8)  ·  Germany (7)  ·  Italy (7)  ·  Netherlands (7)  ·  Norway (5)  ·  Denmark (4)  ·  Israel (3)  ·  Poland (3)  ·  Sweden (3)

Top investigators

George D. Demetri, MD (3)  ·  Benjamin Izar, MD (2)  ·  Ivar Hompland, MD, PhD (2)  ·  Kjetil Boye, MD, PhD (2)  ·  Margaret von Mehren, MD (2)  ·  Mark Dickson, MD (2)  ·  Robert Maki, MD, PhD (2)  ·  Sandra D'Angelo, MD (2)  ·  Seth Pollack (2)  ·  Aaron R Weiss (1)  ·  Alberto Chiappori, M.D. (1)  ·  Alexander Wei, MD (1)  ·  Annabel B.M. Foot (1)

Results publications

PMID 31401903, PMID 32827353, PMID 19451433, PMID 10097144, PMID 11705489, PMID 12528778, PMID 12957454, PMID 15010069, PMID 15177491, PMID 15592836, PMID 15659504, PMID 16528479, PMID 17095209, PMID 17109446, PMID 17336054, PMID 19088049, PMID 19451429, PMID 20338746, PMID 20471824, PMID 20932656, PMID 21642514, PMID 21915260, PMID 22067397, PMID 23382028, PMID 23437092, PMID 23569312, PMID 24215845, PMID 26041763, PMID 27124835, PMID 27502708, PMID 29370992, PMID 30249211, PMID 30410720, PMID 31013172, PMID 31143880, PMID 32002290, PMID 32077895, PMID 32269142, PMID 32641862, PMID 32701199, PMID 32702309, PMID 33180100, PMID 34260265, PMID 34515544, PMID 35115306, PMID 35394800, PMID 35507536, PMID 36129471, PMID 36987836, PMID 37523624

NIH funding

P30CA006516 (3), P30CA015704 (3), P30CA008748 (2), U10CA098543 (2), U10CA180821 (2), UM1CA186709 (2), 2004 (1), 2015 (1), N01CM62203 (1), N01CM62206 (1), P30CA012197 (1), P30CA016672 (1), P30CA060553 (1), R01CA107164 (1), R21CA117128 (1)